UNSPSC 51111769: Vinflunine

This classification denotes a vinca alkaloid compound and vinca-site binding agent with the molecular formula C45H54F2N4O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5BF646324K, chemically known as 4-deoxy-20,20-difluoro-c-norvincaleukoblastine but generally known as vinflunine, which bears US NIH Compound Identifier 157688. European Medicines Agency schedules Vinflunine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00063MIG. The term VINFLUNINE is an International Non-Proprietary Name.

UNSPSC 51111769 Vinflunine is a Commodity code that nominally designates a specific pharmaceutical product, but recent state and local procurement activity under this code shows little direct alignment with vinflunine itself. Instead, the recent solicitations posted under this code span a broader range of pharmaceutical and medical supply procurement — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals distributed through authorized wholesalers. State and local issuing bodies pursuing opportunities under this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), municipal fire departments (City of Tampa Fire Department Rescue Division), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP).

Recent activity spans Florida, Texas, Minnesota, and participating MMCAP member states including Oregon. Representative recent solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023); the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 and SLBE set-aside (due March 13, 2026); MMCAP's RFP to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with responses due March 26, 2026; and the Texas HHS Commission's RFI soliciting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program (response due April 3, 2026). The code shows active procurement across emergency medicine, public health, and cooperative purchasing models, though the mismatch between the nominal commodity (vinflunine, a specific oncology agent) and actual buying patterns suggests this code may be misapplied in state and local systems or used as a catch-all for broader pharmaceutical procurement categories.